Recent Research Projects

The role of FK506 binding protein 51 in the regulation of glucocorticoid receptor signaling

2018/19 • $100,000 • PI,CO
PTSD (post-traumatic stress disorder) occurs in some people after severe traumatic events such as sexual assault or military combat. Patients suffer nightmares, flashbacks, and can be very anxious, avoiding reminders of the traumatic event. In severe cases, PTSD can be completely disabling and...

The role of disrupted-in-schizophrenia-1 in the regulation of dopamine D2 receptor signalling

2012/13-2017/18 • $820,800 • PI
Schizophrenia is a severe, chronic, and debilitating mental disorder. It affects 1 of every 100 Canadians. The disease impacts a vast array of brain systems, seriously affecting a person's thoughts, feelings, and ability to function. Researchers have worked for decades to understand the...

Development and commercialisation of a novel treatment for multiple sclerosis

2016/17 • $299,101 • PI,CO
Treatments for multiple sclerosis need improvement, since current approaches offer incomplete symptom control and do not substantially alter disease outcomes. Most research into multiple sclerosis has focused on the immune system and current treatments are primarily focused on suppressing...

The role of CUL4B in the regulation of dopamine transporter function

2011/12-2014/15 • $225,000 • PI
Parkinson's disease is a brain disorder that impairs ability to move and often progresses to dementia. Degeneration of brain tissue in the midbrain region, specifically neurons which are part of the dopamine neurotransmitter system, is known to be a component of the disease. However, the...

Therapeutics targeting receptor-receptor interactions for Addiction

2010/11 • $150,000 • PI,CO
In Canada, smoking is the greatest preventable cause of illness, disability and premature death, causing more than 45,000 deaths per year. As well, links between health problems such as cancer, heart disease and respiratory disease, and exposure to second-hand smoke are well established (From...

Patents

COMPOSITIONS AND METHODS FOR MODULATING DOPAMINE NEUROTRANSMISSION

The present invention provides for diagnosis or treatment of neurological or neuropsyciatric disorders involving abnormal dopamine neurotransmission. Methods and agents are provided for modulating dopamine transporter activity and modulating dopaminergic neurotransmission. Agents of the present invention include fragments of D2 receptor or dopamine transporter (DAT) that can disrupt D2-DAT coupling.
Related applications: WO2006CA00721, CA20062607095

COMPOSITIONS AND METHODS FOR MODULATING AMPA RECEPTOR-MEDIATED EXCITOTOXICITY

The present invention provides AMPAR excitotoxicity mediating polypeptide s comprising the GluR2 NT1 -3-2 (Y142-K172) amino acid sequence (SEQ ID NO:1 ) or the GAPDH(2-2-1-1) (I221-E250)amino acid sequence (SEQ ID NO:2). Also d isclosed are nucleotide sequences encoding the polypeptides, methods of inhi biting GAPDH association with the GluR2 subunit or p53. Methods of inhibitin g AMPA receptor mediated excitotoxicity using the polypeptides and nucleic a cids are also disclosed.
Related applications: CA20072662026, EP20070800563, WO2007CA01539

COMPOSITIONS AND METHODS FOR MODULATING D1-D2 DOPAMINE RECEPTOR INTERACTION AND FUNCTION

The present invention provides for prevention and/or treatment of neurological or neuropsychiatric disorders involving abnormal D1-D2 dopamine receptor coupling and/or activation. Methods and agents are provided for modulating dopamine receptor function arising from D1-D2 coupling and/or activation. Agents of the present invention include fragments of D2 receptor or D1 receptor that can disrupt D1-D2 coupling.
Related applications: CA20092727086, ES20090761218T, EP20160203535, EP20090761218, EP20090761218, WO2009CA00829

DOPAMINE D2 RECEPTOR-DISC1 INTERACTION, COMPOSITIONS AND METHODS FOR MODULATING SAME

The present invention provides compounds, compositions and methods for inhibiting D2R-DISC1 interaction. Specifically, the present invention provides a polypeptide comprising the amino acid sequence KIYIVLRRRRKRVNT (SEQ ID NO: l) or SEQ ID NO:5, a fragment thereof, or a polypeptide comprising an amino acid sequence that is at least 80% identical to SEQ ID NO: 1 or 5, or a fragment thereof, wherein the polypeptide is not a naturally occurring dopamine receptor. Also provided is a method of...
Related applications: WO2010CA00535, EP20100761161, CA20102756927

COMPOSITIONS AND METHODS FOR MODULATING AMPA RECEPTOR-MEDIATED EXCITOTOXICITY

The present invention provides AMPAR excitotoxicity mediating polypeptides comprising the GluR2 NT 1-3-2 (Y142-K172) amino acid sequence (SEQ ID NO.1), a fragment thereof (SEQ ID NO:6) or the GAPDH(2-2-1-1) (I221 -E250) amino acid sequence (SEQ ID NO:2). Also disclosed are nucleotide sequences encoding the polypeptides, methods of inhibiting GAPDH association with the GluR2 subunit or p53. Methods of inhibiting AMPA receptor mediated excitotoxicity using the polypeptides and nucleic acids...
Related applications: WO2013CA00001

COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS

Disclosed are polypeptides, compositions and methods for the treatment or prophylaxis of multiple sclerosis. The method involves the steps of administering a polypeptide, or nucleic acid encoding the polypeptide, comprising the GluR2 NTal-3-2 (Y142-K172) amino acid sequence as shown by SEQ ID NO: 1 or SEQ ID NO: 5 to a subject in need of the treatment.
Related applications: WO2013CA00002, EP20130733648, CA20132860456

MODULATORS OF AMPA RECEPTOR SIGNALING

The present disclosure relates to compounds of the Formula (I) which have shown utility in modulating AMPA receptor signaling and thus preventing AMPA receptor-mediated toxicity, which may find use in the treatment of diseases in which AMPA receptor activation plays a role in neurodegeneration, including the treatment of multiple sclerosis and other diseases.
Related applications: WO2020IB51920